Logo image of CARA

CARA THERAPEUTICS INC (CARA) Stock Fundamental Analysis

NASDAQ:CARA - Nasdaq - US1407552082 - Common Stock - Currency: USD

5.32  -0.23 (-4.14%)

After market: 5.43 +0.11 (+2.07%)

Fundamental Rating

2

CARA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. The financial health of CARA is average, but there are quite some concerns on its profitability. While showing a medium growth rate, CARA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CARA had negative earnings in the past year.
CARA had a negative operating cash flow in the past year.
CARA had negative earnings in 4 of the past 5 years.
In the past 5 years CARA always reported negative operating cash flow.
CARA Yearly Net Income VS EBIT VS OCF VS FCFCARA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of CARA (-161.70%) is worse than 83.42% of its industry peers.
Industry RankSector Rank
ROA -161.7%
ROE N/A
ROIC N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CARA Yearly ROA, ROE, ROICCARA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

CARA has a Gross Margin of 91.31%. This is amongst the best in the industry. CARA outperforms 93.47% of its industry peers.
CARA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CARA Yearly Profit, Operating, Gross MarginsCARA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

4

2. Health

2.1 Basic Checks

CARA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CARA has more shares outstanding
CARA has less shares outstanding than it did 5 years ago.
CARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CARA Yearly Shares OutstandingCARA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CARA Yearly Total Debt VS Total AssetsCARA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

CARA has an Altman-Z score of -26.56. This is a bad value and indicates that CARA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -26.56, CARA is doing worse than 87.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.56
ROIC/WACCN/A
WACC9.58%
CARA Yearly LT Debt VS Equity VS FCFCARA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 11.03 indicates that CARA has no problem at all paying its short term obligations.
CARA's Current ratio of 11.03 is amongst the best of the industry. CARA outperforms 86.43% of its industry peers.
A Quick Ratio of 10.81 indicates that CARA has no problem at all paying its short term obligations.
CARA has a Quick ratio of 10.81. This is amongst the best in the industry. CARA outperforms 85.93% of its industry peers.
Industry RankSector Rank
Current Ratio 11.03
Quick Ratio 10.81
CARA Yearly Current Assets VS Current LiabilitesCARA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

CARA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -612.03%.
CARA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -66.02%.
The Revenue for CARA have been decreasing by -18.54% on average. This is quite bad
EPS 1Y (TTM)-612.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.05%
Revenue 1Y (TTM)-66.02%
Revenue growth 3Y-32.3%
Revenue growth 5Y-18.54%
Sales Q2Q%-51.56%

3.2 Future

CARA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.45% yearly.
Based on estimates for the next years, CARA will show a very strong growth in Revenue. The Revenue will grow by 68.20% on average per year.
EPS Next Y40%
EPS Next 2Y22.74%
EPS Next 3Y13%
EPS Next 5Y11.45%
Revenue Next Year-25%
Revenue Next 2Y-44.1%
Revenue Next 3Y58.04%
Revenue Next 5Y68.2%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CARA Yearly Revenue VS EstimatesCARA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
CARA Yearly EPS VS EstimatesCARA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CARA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CARA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CARA Price Earnings VS Forward Price EarningsCARA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CARA Per share dataCARA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as CARA's earnings are expected to grow with 13.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.74%
EPS Next 3Y13%

More info and screens

0

5. Dividend

5.1 Amount

CARA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARA THERAPEUTICS INC

NASDAQ:CARA (4/15/2025, 8:00:02 PM)

After market: 5.43 +0.11 (+2.07%)

5.32

-0.23 (-4.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03 2025-03-03/amc
Earnings (Next)05-12 2025-05-12/amc
Inst OwnersN/A
Inst Owner Change-41.88%
Ins OwnersN/A
Ins Owner Change-0.04%
Market Cap24.31M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)22.19%
Min Revenue beat(2)-10.63%
Max Revenue beat(2)55%
Revenue beat(4)2
Avg Revenue beat(4)12.75%
Min Revenue beat(4)-17.21%
Max Revenue beat(4)55%
Revenue beat(8)4
Avg Revenue beat(8)-5.61%
Revenue beat(12)7
Avg Revenue beat(12)-4.97%
Revenue beat(16)8
Avg Revenue beat(16)-9.33%
PT rev (1m)0%
PT rev (3m)1100%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-15.55
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-13.56
FCFYN/A
OCF(TTM)-13.33
OCFYN/A
SpS1.56
BVpS-1.01
TBVpS-1.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -161.7%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.31%
FCFM N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 544.79%
Cap/Sales 14.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.03
Quick Ratio 10.81
Altman-Z -26.56
F-Score4
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)492.59%
Cap/Depr(5y)332.09%
Cap/Sales(3y)8.69%
Cap/Sales(5y)5.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-612.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.05%
EPS Next Y40%
EPS Next 2Y22.74%
EPS Next 3Y13%
EPS Next 5Y11.45%
Revenue 1Y (TTM)-66.02%
Revenue growth 3Y-32.3%
Revenue growth 5Y-18.54%
Sales Q2Q%-51.56%
Revenue Next Year-25%
Revenue Next 2Y-44.1%
Revenue Next 3Y58.04%
Revenue Next 5Y68.2%
EBIT growth 1Y56.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.9%
EBIT Next 3Y10.58%
EBIT Next 5Y5.61%
FCF growth 1Y34.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.84%
OCF growth 3YN/A
OCF growth 5YN/A